🚀 VC round data is live in beta, check it out!
China Res Double-Crane Valuation Multiples
Discover revenue and EBITDA valuation multiples for China Res Double-Crane and similar public comparables like Immunome, Kodiak Sciences, Disc Medicine, Soleno Therapeutics and more.
China Res Double-Crane Overview
About China Res Double-Crane
China Resources Double-Crane Pharmaceutical Co Ltd is a China-based pharmaceutical company. It is engaged in developing, manufacturing and marketing a variety of medical products. The company's products cover different fields such as infusion field, cardiovascular and cerebrovascular fields, pediatrics, endocrine field and other areas.
Founded
1997
HQ
Employees
10.0K
Website
Sectors
Financials (LTM)
EV
$3B
China Res Double-Crane Financials
China Res Double-Crane reported last 12-month revenue of $2B and EBITDA of $382M.
In the same LTM period, China Res Double-Crane generated $945M in gross profit, $382M in EBITDA, and $245M in net income.
Revenue (LTM)
China Res Double-Crane P&L
In the most recent fiscal year, China Res Double-Crane reported revenue of $2B and EBITDA of $401M.
China Res Double-Crane expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $2B | XXX | $2B | XXX | XXX | XXX |
| Gross Profit | $945M | XXX | $936M | XXX | XXX | XXX |
| Gross Margin | 58% | XXX | 58% | XXX | XXX | XXX |
| EBITDA | $382M | XXX | $401M | XXX | XXX | XXX |
| EBITDA Margin | 23% | XXX | 25% | XXX | XXX | XXX |
| EBIT Margin | 17% | XXX | 17% | XXX | XXX | XXX |
| Net Profit | $245M | XXX | $241M | XXX | XXX | XXX |
| Net Margin | 15% | XXX | 15% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
China Res Double-Crane Stock Performance
China Res Double-Crane has current market cap of $3B, and enterprise value of $3B.
Market Cap Evolution
China Res Double-Crane's stock price is $2.68.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $3B | $3B | 0.0% | XXX | XXX | XXX | $0.23 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialChina Res Double-Crane Valuation Multiples
China Res Double-Crane trades at 1.6x EV/Revenue multiple, and 6.8x EV/EBITDA.
EV / Revenue (LTM)
China Res Double-Crane Financial Valuation Multiples
As of April 19, 2026, China Res Double-Crane has market cap of $3B and EV of $3B.
Equity research analysts estimate China Res Double-Crane's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
China Res Double-Crane has a P/E ratio of 11.4x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $3B | XXX | $3B | XXX | XXX | XXX |
| EV (current) | $3B | XXX | $3B | XXX | XXX | XXX |
| EV/Revenue | 1.6x | XXX | 1.6x | XXX | XXX | XXX |
| EV/EBITDA | 6.8x | XXX | 6.5x | XXX | XXX | XXX |
| EV/EBIT | 9.5x | XXX | 9.7x | XXX | XXX | XXX |
| EV/Gross Profit | 2.8x | XXX | 2.8x | XXX | XXX | XXX |
| P/E | 11.4x | XXX | 11.5x | XXX | XXX | XXX |
| EV/FCF | — | XXX | 20.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified China Res Double-Crane Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
China Res Double-Crane Margins & Growth Rates
China Res Double-Crane's revenue in the last 12 month grew by 6%.
China Res Double-Crane's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.
China Res Double-Crane's rule of 40 is 29% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
China Res Double-Crane's rule of X is 37% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
China Res Double-Crane Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 6% | XXX | 5% | XXX | XXX | XXX |
| EBITDA Margin | 23% | XXX | 25% | XXX | XXX | XXX |
| EBITDA Growth | 7% | XXX | 1% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 29% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 37% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 28% | XXX | 28% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 9% | XXX | 9% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 5% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 42% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
China Res Double-Crane Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| China Res Double-Crane | XXX | XXX | XXX | XXX | XXX | XXX |
| Immunome | XXX | XXX | XXX | XXX | XXX | XXX |
| Kodiak Sciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Disc Medicine | XXX | XXX | XXX | XXX | XXX | XXX |
| Soleno Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Veradermics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
China Res Double-Crane M&A Activity
China Res Double-Crane acquired XXX companies to date.
Last acquisition by China Res Double-Crane was on XXXXXXXX, XXXXX. China Res Double-Crane acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by China Res Double-Crane
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialChina Res Double-Crane Investment Activity
China Res Double-Crane invested in XXX companies to date.
China Res Double-Crane made its latest investment on XXXXXXXX, XXXXX. China Res Double-Crane invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by China Res Double-Crane
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout China Res Double-Crane
| When was China Res Double-Crane founded? | China Res Double-Crane was founded in 1997. |
| Where is China Res Double-Crane headquartered? | China Res Double-Crane is headquartered in China. |
| How many employees does China Res Double-Crane have? | As of today, China Res Double-Crane has over 10K employees. |
| Is China Res Double-Crane publicly listed? | Yes, China Res Double-Crane is a public company listed on Shanghai Stock Exchange. |
| What is the stock symbol of China Res Double-Crane? | China Res Double-Crane trades under 600062 ticker. |
| When did China Res Double-Crane go public? | China Res Double-Crane went public in 1997. |
| Who are competitors of China Res Double-Crane? | China Res Double-Crane main competitors are Immunome, Kodiak Sciences, Disc Medicine, Soleno Therapeutics. |
| What is the current market cap of China Res Double-Crane? | China Res Double-Crane's current market cap is $3B. |
| What is the current revenue of China Res Double-Crane? | China Res Double-Crane's last 12 months revenue is $2B. |
| What is the current revenue growth of China Res Double-Crane? | China Res Double-Crane revenue growth (NTM/LTM) is 6%. |
| What is the current EV/Revenue multiple of China Res Double-Crane? | Current revenue multiple of China Res Double-Crane is 1.6x. |
| Is China Res Double-Crane profitable? | Yes, China Res Double-Crane is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of China Res Double-Crane? | China Res Double-Crane's last 12 months EBITDA is $382M. |
| What is China Res Double-Crane's EBITDA margin? | China Res Double-Crane's last 12 months EBITDA margin is 23%. |
| What is the current EV/EBITDA multiple of China Res Double-Crane? | Current EBITDA multiple of China Res Double-Crane is 6.8x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.